Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go:
Extended
investment:
Withheld
Recap is a cryptocurrency portfolio tracking, analytics and tax reporting platform. The company claims that market participants engaging in cryptocurrency have to deal with complex issues such as tracking all of their transactions, valuing cryptocurrency transactions in their tax currency and understanding capital gains tax legislation laws. Recap aims to solve this issue by enabling said participants to calculate any tax they owe on their cryptocurrency trading activity in a matter of seconds on its portal. The company has plans to launch a mobile application enabling investors to track their portfolio on the move. It also intends to come up with a Business-to-business (B2B) offering which Recap asserts will enable crypto native companies to account for their cryptocurrency activity with automatic accounts reconciliation to accounting software like Xero and Quickbooks. The company’s exit strategy is a trade sale within 3-5 years to a cryptocurrency exchange or accounting software provider.
days to go:
Expired
investment:
£120,472
Bippit is a wellbeing platform that provides employees with financial consultancy from a professional with zero cost to the employees themselves. The company asserts that COVID-19 has made financial consultancy services difficult to access for employees. Bippit aims to resolve this situation. It is available in mobile and desktop formats and integrates with an employees’ entire financial life through 'Open Banking'. Bippit argues that this helps staff members receive all the tools they need to learn, plan, and take action concerning their finances. It also helps companies save time and money, ensures that employees receive an impartial support system, and allows financial experts to get an extra revenue stream. The company will launch an Initial Public Offering (IPO) likely within 5 years if it moves beyond strategic acquisition.
days to go:
Expired
investment:
£73,000
Over the past 8 years, Advatech Healthcare has created Hippo, a proven disabled and non-emergency patients transportation services (NEPTS) in the Essex area. Due to its dependability and efficiency, Hippo is now poised to become the UK's best national wheelchair accessible healthcare services on a wearable technology platform. According to the Office for Technology Statistics data, there are 13.37 million people disabled in the UK who lack dedicated non-emergency transportation. Hippo could save the National Health Service (NHS) up to 60% on transportation costs increasing faster hospital bed rotation and providing dedicated transportation for disabled and non-emergency patients with a medically trained staff. It also offers medical and technological necessities not offered by many leading operators. Currently, the company operates within the Essex area. By the end of 2020, the company aims to commence seven new contracts it has signed with the NHS. It also signed a deal with Cambridge Adult Social Care that is expected to close, within a 5-year term and generate over £200,000 per year.
days to go:
Expired
investment:
Withheld
FinOptix is an innovative FinTech company that solves real business problems. FinOptix’s objective is to become a significant player in a rapidly growing FinTech market by developing systems that provide financial clarity to decision-makers. FinOptix has a well-established user base, as well as a sales pipeline that covers multiple geographies and sectors. Their verification and validation procedures applied during the development process and operational trials have led to engagement with commercial partners. With the proceeds, they will design an Evaluator for the future, apply AI techniques to solve complex problems, develop their skill set and framework and hire a team of data scientists based on the assessment.
days to go:
Expired
investment:
£125,000
Revix aims to revolutionise the investing experience for millions of people. It wants to become a platform that makes investing in Alternative Investment Assets (AIA) such as Artificial Intelligence (AI), Biotech, renewable energy, eSports, venture capital, cryptocurrency, and art a simple, engaging and automated affair. The company endeavours to simplify complicated terms so that customers understand what they’re investing in and what the associated risks are. Users can create personalised financial targets and set customised triggers that automatically transfer funds when activated. The company will use 37% of the investment for paying personnel, 42% for marketing, and 21% for security and regulatory advances.
days to go:
Expired
investment:
Withheld
